生长激素缺乏症市场规模、份额及成长分析（按类型、诊断、治疗、给药途径、最终用户和地区）－2025-2032 年产业预测

2023 年生长激素缺乏症市场规模价值 37 亿美元，预计将从 2024 年的 39 亿美元成长到 2032 年的 59.9 亿美元，预测期间（2025-2032 年）的复合年增长率为 5.5%。

由于遗传性疾病、脑损伤和某些医疗手段等因素导致的生长激素缺乏症（GHD）发生率不断上升，大大推动了对生长激素治疗的需求。根据美国国家生物技术资讯中心 (NCBI) 的资料，英国每 3,500 到 4,000 名儿童中约有 1 名患有 GHD，因此对有效治疗的需求日益增长。这种日益流行的趋势正在刺激产业的扩张，而强大的研发能力则是其发展的先导。 2022 年 2 月，辉瑞和 OPKO 获得了欧盟 (EU) 每週一次的 NGENLA™ (somatrogon) 注射的上市核准，这是生长激素治疗领域的一个重要里程碑，进一步巩固了该行业的成长轨迹。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

生长激素缺乏症市场规模（按类型）

• 市场概览
• 儿童生长激素缺乏症
• 成人生长激素缺乏症

生长激素缺乏症市场规模（依诊断）

• 市场概览
• 血液检查
• 影像检查
• 电脑断层扫描 (CT)
• 磁振造影（MRI）
• 其他的

生长激素缺乏症治疗市场规模

• 市场概览
• 药物治疗
• 重组人体生长荷尔蒙
• 人类脑下垂体萃取物
• 外科手术

按给药途径分類的生长激素缺乏症市场规模

• 市场概览
• 静脉
• 肌肉注射
• 其他的

生长激素缺乏症市场规模（依最终用户划分）

• 市场概览
• 医院
• 居家护理
• 专科诊所
• 其他的

生长激素缺乏症市场规模（依分销管道）

• 市场概览
• 医院药房
• 网路药局
• 零售药局

生长激素缺乏症市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Novo Nordisk A/S（Denmark）
• Ipsen SA（France）
• Ascendis Pharma A/S（Denmark）
• Ferring Pharmaceuticals（Switzerland）
• OPKO Health Inc.（USA）
• Genexine, Inc.（South Korea）
• LG Chem Ltd.（South Korea）
• Anhui Anke Biotechnology（China）
• Teva Pharmaceutical Industries Ltd.（Israel）
• JCR Pharmaceuticals Co., Ltd.（Japan）
• Shanghai United Cell Biotechnology Co., Ltd.（China）
• Hanmi Pharmaceutical Co., Ltd.（South Korea）
• Strongbridge Biopharma plc（USA）
• GeneScience Pharmaceuticals Co., Ltd.（China）
• Cipla Limited（India）
• BIOCAD（Russia）
• Krka, dd（Slovenia）
• OPBIO Factory Co., Ltd.（South Korea）

结论和建议

Growth Hormone Deficiency Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 3.9 billion in 2024 to USD 5.99 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The rising incidence of growth hormone deficiency (GHD), driven by factors like genetic disorders, brain injuries, and specific medical treatments, is significantly boosting the demand for growth hormone therapies. Data from the National Center for Biotechnology Information (NCBI) indicates that approximately 1 in every 3,500-4,000 children in the UK is affected by pediatric GHD, highlighting a growing need for effective treatments. This increasing prevalence is catalyzing industry expansion, with robust research and development at the forefront. A notable advancement occurred in February 2022 when Pfizer and OPKO received European Union marketing authorization for their Once-Weekly NGENLA(TM) (somatrogon) Injection, marking an important milestone in the growth hormone therapy landscape and further cementing the industry's growth trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segments Analysis

Global Growth Hormone Deficiency Market is segmented by Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Diagnosis, the market is segmented into Blood Tests, Imaging Tests, Computerized tomography (CT) scans, Magnetic resonance imaging (MRI) and Others. Based on Treatment, the market is segmented into Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery. Based on Route of Administration, the market is segmented into Intravenous, Intramuscular and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Growth Hormone Deficiency Market

One of the key market drivers for the global growth hormone deficiency market is the increasing prevalence of growth hormone deficiency and related disorders among children and adults. This rise is partly attributed to better diagnosis and awareness, leading to earlier identification and treatment. Additionally, lifestyle factors, such as sedentary habits and rising obesity rates, contribute to hormonal imbalances, further fueling the need for growth hormone therapies. As healthcare providers continue to emphasize the importance of addressing growth issues and improving quality of life, the demand for effective growth hormone treatments is expected to grow significantly in the coming years.

Restraints in the Growth Hormone Deficiency Market

The market for Growth Hormone Deficiency faces significant restraints, primarily due to the high costs associated with Human Growth Hormone (HGH) therapy. This financial burden limits accessibility for various patient groups and places considerable strain on healthcare systems. A 2022 medical journal study highlighted the extensive financial challenges faced by patients and healthcare providers alike, emphasizing the need for more affordable treatment options. Addressing these economic hurdles is crucial for enhancing access to HGH therapy, prompting calls for the development of cost-effective solutions and pricing reforms to ensure that more individuals can benefit from necessary treatments without extreme financial hardship.

Market Trends of the Growth Hormone Deficiency Market

The Growth Hormone Deficiency (GHD) market is experiencing a noteworthy shift driven by innovative advancements in drug delivery systems. The introduction of wearable patches, needle-free devices, and autoinjectors enhances patient convenience and compliance, transforming how growth hormone therapies are administered. Additionally, the rise of long-acting formulations and implantable devices allows for extended-release options, significantly reducing the frequency of dosing. These innovations not only improve treatment efficacy but also elevate patient experiences, enabling wider accessibility to essential therapies. As the industry embraces these developments, the GHD market is set for robust growth, highlighting significant opportunities for pharmaceutical companies and healthcare providers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Growth Hormone Deficiency Market Size by Type & CAGR (2025-2032)

• Market Overview
• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency

Global Growth Hormone Deficiency Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Imaging Tests
• Computerized tomography (CT) scans
• Magnetic resonance imaging (MRI)
• Others

Global Growth Hormone Deficiency Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Pharmacological Therapy
• Recombinant Human Growth Hormone
• Human Pituitary Gland Extracts
• Surgery

Global Growth Hormone Deficiency Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Intramuscular
• Others

Global Growth Hormone Deficiency Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Growth Hormone Deficiency Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Growth Hormone Deficiency Market Size & CAGR (2025-2032)

• North America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genexine, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai United Cell Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOCAD (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d. (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPBIO Factory Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations